- Home
- ACRS vs VBF Comparison
ACRS vs VBF Comparison
Compare ACRS & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- VBF
- Stock Information
- Founded
- ACRS 2012
- VBF 1970
- Country
- ACRS United States
- VBF United States
- Employees
- ACRS N/A
- VBF N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- VBF Trusts Except Educational Religious and Charitable
- Sector
- ACRS Health Care
- VBF Finance
- Exchange
- ACRS Nasdaq
- VBF Nasdaq
- Market Cap
- ACRS 165.7M
- VBF 177.8M
- IPO Year
- ACRS 2015
- VBF N/A
- Fundamental
- Price
- ACRS $1.53
- VBF $15.48
- Analyst Decision
- ACRS Strong Buy
- VBF
- Analyst Count
- ACRS 9
- VBF 0
- Target Price
- ACRS $9.25
- VBF N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- VBF 45.5K
- Earning Date
- ACRS 08-11-2025
- VBF 01-01-0001
- Dividend Yield
- ACRS N/A
- VBF 5.18%
- EPS Growth
- ACRS N/A
- VBF N/A
- EPS
- ACRS N/A
- VBF N/A
- Revenue
- ACRS $17,777,000.00
- VBF N/A
- Revenue This Year
- ACRS N/A
- VBF N/A
- Revenue Next Year
- ACRS $8.11
- VBF N/A
- P/E Ratio
- ACRS N/A
- VBF N/A
- Revenue Growth
- ACRS N/A
- VBF N/A
- 52 Week Low
- ACRS $1.05
- VBF $13.68
- 52 Week High
- ACRS $5.17
- VBF $16.27
- Technical
- Relative Strength Index (RSI)
- ACRS 47.05
- VBF 55.94
- Support Level
- ACRS $1.46
- VBF $15.29
- Resistance Level
- ACRS $1.86
- VBF $15.40
- Average True Range (ATR)
- ACRS 0.12
- VBF 0.11
- MACD
- ACRS -0.02
- VBF 0.01
- Stochastic Oscillator
- ACRS 17.54
- VBF 68.23
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.